Prevail Therapeutics
Clinical trials sponsored by Prevail Therapeutics, explained in plain language.
-
New gene therapy targets Parkinson's in patients with specific gene flaw
Disease control OngoingThis early-stage study tests a gene therapy called LY3884961 in 32 people with moderate to severe Parkinson's disease who have a specific genetic change (GBA1 mutation). The treatment is given as a single injection into the fluid around the brain and spinal cord. The main goal is…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New gene therapy targets rare dementia at its genetic root
Disease control OngoingThis study tests a single-dose gene therapy (LY3884963) in 35 adults with frontotemporal dementia caused by a progranulin gene mutation. The goal is to see if it safely raises progranulin levels in the body and brain, which may slow disease progression. Participants receive one o…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Gene therapy hope for babies with fatal brain disease
Disease control OngoingThis study tests a single-dose gene therapy (LY3884961) in 7 infants with Type 2 Gaucher disease, a severe and life-limiting condition. The treatment aims to correct the genetic defect to slow or stop disease progression. Researchers will monitor safety, side effects, and how wel…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated May 18, 2026 12:09 UTC